Program
Dronabinol
Also written as “Dronabinol Oral Solution”, “GW-2000-02” and “SP-104”.
Its studies are mostly in Pain · Fasting · Vomiting · Sleep Apnea, Obstructive · Cancer Pain, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| INSYS Therapeutics | 30 open or running | phase 1since Oct 5, 2011 | Oct 5, 2011 | none ahead |
| Jazz Pharmaceuticals | 30 open or running | phase 3since Apr 28, 2008 | Apr 28, 2008 | none ahead |
| Abbott | 20 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Scilex Pharmaceuticals | 20 open or running | phase 1since Jul 6, 2021 | Jul 6, 2021 | none ahead |
| Benuvia Therapeutics | 11 open or running | phase 3since Feb 11, 2026 | Feb 11, 2026 | May 30, 2028phase 3 · NCT07422311 |
| bionorica-research-gmbh | 10 open or running | phase 3since Aug 13, 2009 | Aug 13, 2009 | none ahead |
| CannaXan | 10 open or running | phase 1since Feb 24, 2022 | Feb 24, 2022 | none ahead |
| daisy-pharma-opioid-venture-llc | 10 open or running | phase 2since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| FG Brasil LTDA | 10 open or running | phase 3since Mar 8, 2022 | Mar 8, 2022 | none ahead |
| Incannex Healthcare | 11 open or running | phase 2since Jun 3, 2026 | Jun 3, 2026 | Apr 2027phase 2 · NCT07635563 |
| Par Health | 10 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| scisparc | 10 open or running | phase 2since Aug 9, 2018 | Aug 9, 2018 | none ahead |
| Sobereye | 10 open or running | no phasesince Apr 14, 2025 | Apr 14, 2025 | none ahead |
| ZYUS Life Sciences | 10 open or running | phase 2since Jul 25, 2024 | Jul 25, 2024 | none ahead |
Also a collaborator on its studies: KGK Science and fgk-clinical-research-gmbh.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Mar 21, 2008.
- Oct 5, 2011INSYS Therapeutics's first study: phase 1 study in FastingNew to INSYS TherapeuticsINSYS Therapeutics · NCT01448772 · 88 enrolled · United States
- May 23, 2012Phase 3 study in PainJazz Pharmaceuticals · NCT01606189 · 48 enrolled · United Kingdom
- Mar 14, 2014Phase 1 study in Substance-Related DisordersINSYS Therapeutics · NCT02094599 · 43 enrolled · Canada
- Nov 12, 2015No phase study in HealthyINSYS Therapeutics · NCT02604992 · 54 enrolled · United States
- Aug 9, 2018scisparc's first study: phase 2 study in Tourette SyndromeNew to scisparcscisparc · NCT03651726 · 60 enrolled · Germany
- Nov 30, 2018daisy-pharma-opioid-venture-llc's first study: phase 2 study in Chronic PainNew to daisy-pharma-opioid-venture-llcdaisy-pharma-opioid-venture-llc · NCT03766269 · 280 enrolled · United States
- Jul 6, 2021Scilex Pharmaceuticals's first study: phase 1 study in Healthy VolunteersNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT04958876 · 52 enrolled · New Zealand
- Aug 5, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT05002946 · 18 enrolled · New Zealand
- Feb 24, 2022CannaXan's first study: phase 1 study in Marijuana AbuseNew to CannaXanCannaXan · NCT05267769 · 12 enrolled · Germany
- Mar 8, 2022FG Brasil LTDA's first study: phase 3 study in FibromyalgiaNew to FG Brasil LTDAFG Brasil LTDA · NCT05283161 · 40 enrolled
- Jul 25, 2024ZYUS Life Sciences's first study: phase 2 study in Cancer PainNew to ZYUS Life SciencesZYUS Life Sciences · NCT06533657 · 11 enrolled · Canada
- Apr 14, 2025Sobereye's first study: no phase study in Cannabis IntoxicationNew to SobereyeSobereye · NCT06967051 · 20 enrolled · Canada
- Feb 11, 2026Benuvia Therapeutics's first study: phase 3 study in Aberrant Motor Behavior in DementiaNew to Benuvia TherapeuticsBenuvia Therapeutics · NCT07422311 · 140 planned · Australia
- Jun 3, 2026Incannex Healthcare's first study: phase 2 study in Sleep Apnea, ObstructiveNew to Incannex HealthcareIncannex Healthcare · NCT07635563 · 120 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Sleep Apnea, ObstructiveIncannex Healthcare · NCT07635563
- May 30, 2028Primary completion: phase 3 study in Aberrant Motor Behavior in DementiaBenuvia Therapeutics · NCT07422311
TargetBeta
“Cannabinoid CB1 receptor agonist”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Cannabidiolrule | Jazz Pharmaceuticals | phase 4 | 68 |
| Rimonabantrule | Sanofi | phase 3 | 38 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07635563Sleep Apnea, Obstructive · United States | 2 | Recruiting | Incannex Healthcare | Apr 2027 | 120 |
| NCT07422311Aberrant Motor Behavior in Dementia · Australia | 3 | Not yet recruiting | Benuvia Therapeutics | May 30, 2028 | 140 |
| NCT06967051Cannabis Intoxication · Canada | – | Completed | Sobereye | Aug 19, 2025 | 20 |
| NCT06533657Cancer Pain · Canada | 2 | Completed | ZYUS Life Sciences | Apr 15, 2026 | 11 |
| NCT05283161Fibromyalgia | 3 | UNKNOWN | FG Brasil LTDA | Aug 20, 2022 | 40 |
| NCT05267769Marijuana Abuse · Germany | 1 | Completed | CannaXan | Apr 3, 2022 | 12 |
| NCT05002946Healthy · New Zealand | 1 | Completed | Scilex Pharmaceuticals | Apr 24, 2022 | 18 |
| NCT04958876Healthy Volunteers · New Zealand | 1 | Completed | Scilex Pharmaceuticals | Dec 20, 2021 | 52 |
| NCT03766269Chronic Pain · United States | 2 | UNKNOWN | daisy-pharma-opioid-venture-llc | Jun 1, 2019 | 280 |
| NCT03651726Tourette Syndrome · Germany | 2 | UNKNOWN | scisparc | Nov 2019 | 60 |
| NCT02604992Healthy · United States | – | Completed | INSYS Therapeutics | Dec 2015 | 54 |
| NCT02094599Substance-Related Disorders · Canada | 1 | Completed | INSYS Therapeutics | May 2014 | 43 |
| NCT01606189Pain · United Kingdom | 3 | Completed | Jazz Pharmaceuticals | Sep 2002 | 48 |
| NCT01448772Fasting · United States | 1 | Completed | INSYS Therapeutics | Dec 2011 | 88 |
| NCT01380457Fasting · United States | 1 | Completed | Par Health | Apr 2006 | 69 |
| NCT00959218Multiple Sclerosis · Germany | 3 | Completed | bionorica-research-gmbh | Mar 2010 | 240 |
| NCT00675948Pain · United Kingdom | 3 | Completed | Jazz Pharmaceuticals | Sep 2006 | 43 |
| NCT00674609Pain · United Kingdom | 3 | Completed | Jazz Pharmaceuticals | Feb 2004 | 177 |
| NCT00642512Vomiting · United States | 3 | Completed | Abbott | Jul 2004 | 64 |
| NCT00642499Vomiting · United States | 2 | Completed | Abbott | Apr 2005 | 103 |
How it is read
Names in the registry
- “Dronabinol”, 4 entries
- “Dronabinol Oral Solution”, 2 entries
- “GW-2000-02”, 2 entries
- “SP-104”, 2 entries
- “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
Codes read as this program: GW200002.
Conditions, from the studies’ own filings
- Pain, 3 studies
- Fasting, 2 studies
- Vomiting, 2 studies
- Sleep Apnea, Obstructive, 1 study
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.